Get the Stockscreener App
1.78
1.14%
0.02
After Hours:
1.85
0.07
+3.93%
Quince Therapeutics Inc stock is traded at $1.78, with a volume of 95,151.
It is up +1.14% in the last 24 hours and down -3.26% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
See More
Previous Close:
$1.76
Open:
$1.76
24h Volume:
95,151
Relative Volume:
0.17
Market Cap:
$78.32M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-2.1446
EPS:
-0.83
Net Cash Flow:
$-18.45M
1W Performance:
-12.32%
1M Performance:
-3.26%
6M Performance:
+173.85%
1Y Performance:
+60.36%
1-Day Range:
$1.74
$1.847
1-Week Range:
$1.74
$2.055
52-Week Range:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.78 | 78.32M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Quince Therapeutics Inc Stock (QNCX) Latest News
Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World
Brookline Capital Management Predicts QNCX FY2024 Earnings - MarketBeat
Quince Therapeutics initiated with a Buy at Brookline - MSN
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Brookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com
Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat
QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics regains Nasdaq compliance - Investing.com
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
Quince Therapeutics reports positive safety data for EryDex - Investing.com India
Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK
Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan
Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
US Penny Stocks To Watch In October 2024 - Yahoo Finance
Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada
Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World
Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily
Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News
Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News
Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com India
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Jun 04 '24 |
Option Exercise |
0.55 |
56,061 |
30,834 |
257,616 |
| Thye Dirk | CHIEF EXECUTIVE OFFICER |
Jan 16 '24 |
Option Exercise |
0.79 |
240,530 |
190,791 |
689,441 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):